We are live on ! Find out more
BCTXZ

BriaCell Therapeutics Corp Warrant
BCTXZ

4 hedge funds and large institutions have $199K invested in BriaCell Therapeutics Corp Warrant in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

2.54% less ownership

Funds ownership: 63.37% → 60.84% (-2.5%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

54% less capital invested

Capital invested by funds: $434K → $199K (-$235K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$787

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$9.94K
2
HCM
Heights Capital Management
California
-$772
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
1
Empery Asset Management
New York
$93.3K – – –
HCM
2
Heights Capital Management
California
$75.6K -$772 -4,600 -0.8%
SM
3
Sabby Management
Florida
$28.9K -$9.94K -59,211 -22%
UBS Group
4
UBS Group
Switzerland
$658 +$787 +4,692 +93,840%

BCTXZ Hedge Fund Activity: Q1 2026 in Review

4 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Corp Warrant (BCTXZ) for Q1 2026, worth a combined $199K — down 54% from $434K a quarter earlier.

Fund positioning in BCTXZ was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was UBS Group, adding an estimated $787. The largest seller was Sabby Management, cutting an estimated $9.94K.

  • 4 institutional investors held BriaCell Therapeutics Corp Warrant (BCTXZ) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $199K of BriaCell Therapeutics Corp Warrant stock for Q1 2026, down 54% quarter-over-quarter.
  • 0 funds opened new BriaCell Therapeutics Corp Warrant positions in Q1 2026 and 0 closed out.
  • The largest BriaCell Therapeutics Corp Warrant buyer in Q1 2026 was UBS Group, an estimated $787 added.
  • The largest BriaCell Therapeutics Corp Warrant seller in Q1 2026 was Sabby Management, an estimated $9.94K sold.

Based on aggregated 13F filings for Q1 2026.